文献速递胸部CT

器官型管电流调制与锡预滤过光谱成形对比:铋乳腺屏蔽在低剂量肺部CT中能增加什么

Organ-based tube current modulation versus spectral shaping via tin prefiltration: What does bismuth breast shielding add in low-dose lung CT?
PubMed 文献 · Eur J Radiol · 2023-10-18

在Alderson-Rando体模上比较标准120kVp、器官型管电流调制(OBTCM)100kVp与锡预滤过100kVp三对协议(无/有乳腺屏蔽)的辐射剂量与图像质量。标准与OBTCM协议间等效剂量无显著差异(p≥0.068),锡预滤过协议等效剂量显著更低(p≤0.003)。铋屏蔽在OBTCM联合时有效剂量降低19.8%,在锡预滤过时降低13.9%,标准协议仅降低8.0%。

要点

  • 锡预滤过协议有效剂量最低(0.7/0.6 mSv),铋屏蔽进一步降低13.9%。
  • OBTCM联合铋屏蔽有效剂量降低19.8%,但标准与OBTCM间无显著差异。
  • 主观评估偏好标准协议P1而非锡预滤过低剂量扫描(p≤0.032),但所有协议图像质量均满足诊断要求。

核心结论

  • 铋乳腺屏蔽与OBTCM联合时获益尤其明显,而锡预滤过光谱成形在可接受图像质量下实现最显著的肺部CT剂量降低。

研究设计与样本

  • 实验研究,使用Alderson-Rando体模,三对扫描协议(P1/P2标准120kVp、P3/P4 OBTCM 100kVp、P5/P6锡预滤过100kVp),无/有乳腺屏蔽,热释光剂量计测量11个位点等效剂量,计算剂量加权对比噪声比(CNRD),四位放射科医师独立评估图像质量。

诊断标准与关键数值

  • 标准协议P1/P2有效剂量为7.3/6.8 mSv,乳腺屏蔽降低8.0%。
  • OBTCM协议P3/P4有效剂量为6.6/5.3 mSv,乳腺屏蔽降低19.8%。
  • 锡预滤过协议P5/P6有效剂量为0.7/0.6 mSv,乳腺屏蔽降低13.9%。
  • 标准与OBTCM协议间等效剂量无显著差异(p≥0.068),锡预滤过协议等效剂量显著更低(p≤0.003)。

临床应用与阅片要点

  • 作者结论认为铋乳腺屏蔽与OBTCM联合时获益尤其明显,锡预滤过光谱成形在可接受图像质量下实现最显著的肺部CT剂量降低。
  • 主观评估偏好标准协议P1而非锡预滤过低剂量扫描(p≤0.032),但所有协议图像质量均满足诊断要求。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: Since organ-based tube current modulation (OBTCM) and tin prefiltration are limited on their own in lowering the dose of lung CT examinations, this experimental study was designed to investigate whether combinations with anterior patient shielding can increase the dose reduction potential.

MATERIAL AND METHODS: Three pairs of scan protocols without/with breast shield (P1/P2: standard 120kVp, P3/P4: OBTCM at 100 kVp, P5/P6: Sn 100 kVp) were employed for radiation exposure and image quality comparisons on an anthropomorphic Alderson-Rando phantom. Equivalent doses were measured in eleven sites via thermoluminescent dosimetry and the effective dose was obtained by summation of the weighted organ doses. Dose-weighted contrast-to-noise ratios (CNRD) were calculated and four radiologists independently assessed the quality of images generated with each protocol.

RESULTS: While no significant difference was determined between standard and OBTCM protocols regardless of breast shield (p ≥ 0.068), equivalent doses with spectral shaping were substantially lower (p ≤ 0.003). The highest effective dose was ascertained for standard scans (P1/P2: 7.3/6.8 mSv) with a dose reduction of 8.0 % via breast shielding. The use of a bismuth shield was more beneficial in OBTCM (P3/P4: 6.6/5.3 mSv) and spectral shaping (P5/P6: 0.7/0.6 mSv), reducing the effective dose by 19.8 % and 13.9 %, respectively. Subjective assessment favoured standard protocol P1 over tin prefiltration low-dose scans (p ≤ 0.032), however, no scan protocol entailed diagnostically insufficient image quality.

CONCLUSIONS: Whereas breast shielding is particularly beneficial in combination with OBTCM, spectral shaping via tin prefiltration facilitates the most pronounced dose reduction in lung CT imaging with acceptable image quality.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Feldle P, Grunz JP, Huflage H, et al. Organ-based tube current modulation versus spectral shaping via tin prefiltration: What does bismuth breast shielding add in low-dose lung CT? Eur J Radiol. 2023. PMID: 37871356. doi:10.1016/j.ejrad.2023.111157

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。